JP2008524235A - オクトレオチド化合物の徐放性送達処方物 - Google Patents

オクトレオチド化合物の徐放性送達処方物 Download PDF

Info

Publication number
JP2008524235A
JP2008524235A JP2007546882A JP2007546882A JP2008524235A JP 2008524235 A JP2008524235 A JP 2008524235A JP 2007546882 A JP2007546882 A JP 2007546882A JP 2007546882 A JP2007546882 A JP 2007546882A JP 2008524235 A JP2008524235 A JP 2008524235A
Authority
JP
Japan
Prior art keywords
octreotide
implant
atrigel
composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007546882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524235A5 (enExample
Inventor
スティーブン エル． ウォーレン，
エリック ダデイ，
リチャード エル． ダン，
ジョン ミルトン ダウニング，
エレン チ リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2008524235A publication Critical patent/JP2008524235A/ja
Publication of JP2008524235A5 publication Critical patent/JP2008524235A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2007546882A 2004-12-15 2005-12-15 オクトレオチド化合物の徐放性送達処方物 Pending JP2008524235A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627304P 2004-12-15 2004-12-15
PCT/US2005/045346 WO2006065951A2 (en) 2004-12-15 2005-12-15 Sustained delivery formulations of octreotide compounds

Publications (2)

Publication Number Publication Date
JP2008524235A true JP2008524235A (ja) 2008-07-10
JP2008524235A5 JP2008524235A5 (enExample) 2009-01-29

Family

ID=36588524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007546882A Pending JP2008524235A (ja) 2004-12-15 2005-12-15 オクトレオチド化合物の徐放性送達処方物

Country Status (6)

Country Link
US (1) US20090092650A1 (enExample)
EP (1) EP1838285A2 (enExample)
JP (1) JP2008524235A (enExample)
AU (1) AU2005316545A1 (enExample)
CA (1) CA2590696A1 (enExample)
WO (1) WO2006065951A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512147A (ja) * 2008-12-15 2012-05-31 ノバルティス アーゲー 一定して高い曝露レベルを有するオクトレオチドのデポー製剤
JP2013522239A (ja) * 2010-03-12 2013-06-13 サーモディクス，インコーポレイテッド 注射用薬物送達システム
JP2018522906A (ja) * 2015-08-03 2018-08-16 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PT2079767E (pt) * 2006-10-11 2014-10-07 Tolmar Therapeutics Inc Preparação de poliésteres biodegradáveis com propriedades de baixa rotura por extração com fluido supercrítico
MX354603B (es) 2007-05-25 2018-03-13 Indivior Uk Ltd Formulaciones de transferencia sostenida de compuestos de risperidona.
US8877225B2 (en) 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9155745B2 (en) * 2009-06-16 2015-10-13 Universite De Geneve Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
EP2464389A2 (en) 2009-08-06 2012-06-20 Koninklijke Philips Electronics N.V. Oncology therapies employing radioactive seeds
WO2011087496A1 (en) * 2010-01-13 2011-07-21 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide without an initial time lag
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
MX368683B (es) 2012-08-30 2019-10-11 Pilot Polymer Tech Inc Agentes espesantes de mecanismo dual para fluidos de fracturación hidráulica.
EP2951220B1 (en) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Salt-tolerant star macromolecules
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2956431C (en) 2014-07-03 2023-01-31 ATRP Solutions, Inc. Surfactant-compatible star macromolecules
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
WO2017083800A1 (en) * 2015-11-13 2017-05-18 Ohr Pharmaceutical, Inc. Occult cnv size as a predictor for treatment with squalamine
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
JP2022506554A (ja) * 2018-10-29 2022-01-17 プージン ケミカル インダストリー カンパニー リミテッド 耐高温性、耐老化性ポリグリコライドコポリマーおよびその組成
WO2020087205A1 (en) * 2018-10-29 2020-05-07 Pujing Chemical Industry Co., Ltd Polyglycolide copolymer and preparation tehreof
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN113318218A (zh) * 2021-07-20 2021-08-31 国药一心制药有限公司 一种醋酸奥曲肽注射液及其制备工艺
CN120131956A (zh) * 2023-12-11 2025-06-13 中山大学中山眼科中心 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
WO2004043222A2 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
WO2004045633A2 (en) * 2002-11-19 2004-06-03 Novartis Ag Pharmaceutical composition comprising octreotide microparticles
JP2004516263A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
JP2004517146A (ja) * 2001-01-26 2004-06-10 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 生物活性物質カプセル化生分解性高分子の微粒子および該微粒子を含有する徐放性医薬配合物
WO2004078922A2 (en) * 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004516263A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 疎水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
JP2004517146A (ja) * 2001-01-26 2004-06-10 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 生物活性物質カプセル化生分解性高分子の微粒子および該微粒子を含有する徐放性医薬配合物
WO2004043222A2 (en) * 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
WO2004045633A2 (en) * 2002-11-19 2004-06-03 Novartis Ag Pharmaceutical composition comprising octreotide microparticles
WO2004078922A2 (en) * 2003-02-28 2004-09-16 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512147A (ja) * 2008-12-15 2012-05-31 ノバルティス アーゲー 一定して高い曝露レベルを有するオクトレオチドのデポー製剤
JP2013522239A (ja) * 2010-03-12 2013-06-13 サーモディクス，インコーポレイテッド 注射用薬物送達システム
JP2018522906A (ja) * 2015-08-03 2018-08-16 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
US11779589B2 (en) 2015-08-03 2023-10-10 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US12447158B2 (en) 2015-08-03 2025-10-21 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs

Also Published As

Publication number Publication date
WO2006065951A3 (en) 2006-10-19
AU2005316545A1 (en) 2006-06-22
US20090092650A1 (en) 2009-04-09
WO2006065951A2 (en) 2006-06-22
EP1838285A2 (en) 2007-10-03
CA2590696A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
JP2008524235A (ja) オクトレオチド化合物の徐放性送達処方物
JP7297116B2 (ja) 前立腺癌を治療するための組成物
CN104248623B (zh) 使用非水性载体的持续释放制剂
KR101466933B1 (ko) 펩타이드의 지속 방출 전달을 위한 의약 조성물
AU2009268480C1 (en) Delivery of dry formulations of octreotide
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
KR20140105527A (ko) 강력한 방출-조절된 펩티드 제형
EP2164473B1 (en) An extended-release composition comprising a somatostatin derivative in microparticles
US20250018004A1 (en) Pharmaceutical Compositions having a Selected Release Duration
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
US20250319099A1 (en) Method of administering a hormone encapsulated by a hydrogel with a dual chamber syringe
CN118103030A (zh) 可注射的高浓度药物制剂及其制造和使用方法
US20250249067A1 (en) Delivery of dry formulations of octreotide
JP2001510811A (ja) 生物活性物質を標的に供給するための重合体ベースの薬剤組成物
WO2009148583A2 (en) Method for improvement of octreotide bioavailability
CA3084339C (en) Pharmaceutical compositions having a selected release duration
Fan et al. Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits
KR20250035949A (ko) 성장호르몬 마이크로니들 제조용 점액 조성물, 이를 이용하여 제조되는 성장호르몬 마이크로니들 구조체, 상기 마이크로니들 구조체를 포함하는 마이크로니들 패치 및 마이크로어레이
Cunningham et al. Formulation of depot delivery systems
NZ766167B2 (en) Pharmaceutical compositions having a selected release duration
HK1141248B (en) An extended-release composition comprising a somatostatin derivative in microparticles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120120